CELL AND GENE THERAPY INSIGHTS

February 2023 Issue

Volume 9 Issue 1

Cell and Gene Therapy Insights Volume 9 Issue 1
Download PDF

Featuring

Issue Spotlight: Preclinical & translational R&D
Vectors focus: Scalability
Other articles
Webinars

SPOTLIGHT

Preclinical & translational R&D
Sven Kili
Guest Editor:
Sven Kili, CEO at Antion Biosciences

Interview

Assessing the evolving AAV preclinical safety landscape in 2023 & beyond

Assessing the evolving AAV preclinical safety landscape in 2023 & beyond

Basel Assaf
4 April 2023
Read
Navigating the path to clinic for ATMPs: a regulator’s perspective

Navigating the path to clinic for ATMPs: a regulator’s perspective

James W McBlane
2 February 2023
Read
Preclinical toolkit evolution for cancer vaccines & CAR-T cell therapy

Preclinical toolkit evolution for cancer vaccines & CAR-T cell therapy

Adam Snook
18 January 2023
Read

Viewpoint

Preclinical safety assessment in therapeutic genome editing

Preclinical safety assessment in therapeutic genome editing

Roberto Nitsch
10 March 2023
Read
Addressing gene therapy translational R&D bottlenecks in the CNS

Addressing gene therapy translational R&D bottlenecks in the CNS

Anindya Sen
9 March 2023
Read
Key considerations when translating a cell therapy product into the clinic

Key considerations when translating a cell therapy product into the clinic

Anthony Ting
6 February 2023
Read

Vectors FOCUS

Scalability

Interview

Sharing best practices in AAV vector scale-up

Sharing best practices in AAV vector scale-up

Seth Levy
16 January 2023
Read

Podcast

Maximizing efficiency & flexibility in viral vector manufacturing scale-up

Maximizing efficiency & flexibility in viral vector manufacturing scale-up

D Kole, J Petrone, M Bisschops et al.
7 March 2023
Listen

EBook

Analytical innovation: meeting the demands of commercial viral vector manufacture

Analytical innovation: meeting the demands of commercial viral vector manufacture

15 March 2023
Read

Journal articles

Research Article

Advanced therapies, hospital exemptions & marketing authorizations: the UK’s emerging regulatory framework for point-of-care manufacture

Advanced therapies, hospital exemptions & marketing authorizations: the UK’s emerging regulatory framework for point-of-care manufacture

Edison Bicudo, Irina Brass
23 February 2023
Read

Expert Insight

Implementing demand & operations planning in clinical cell & gene therapy

Implementing demand & operations planning in clinical cell & gene therapy

Peter Horton
26 January 2023
Read

Innovator Insight

Simplifying lentiviral downstream processing with a novel affinity resin & robust analytical tools

Simplifying lentiviral downstream processing with a novel affinity resin & robust analytical tools

Chantelle Gaskin, Suzy Brown
9 July 2024
Read
Commercializing cell & gene therapies: a perspective from the quality function

Commercializing cell & gene therapies: a perspective from the quality function

Christoph Meyer, Andreas Wirth
9 February 2023
Read
Enhancing non-viral gene editing, processing & expansion of T & NK cells

Enhancing non-viral gene editing, processing & expansion of T & NK cells

6 February 2023
Read

Interview

Exploring the potential of insect cell lines for efficient AAV production

Exploring the potential of insect cell lines for efficient AAV production

20 March 2023
Read
Seizing the day: addressing the urgent need for standards development in regenerative medicine

Seizing the day: addressing the urgent need for standards development in regenerative medicine

Richard McFarland
15 March 2023
Read
Vaccines & beyond: a decade in mRNA delivery

Vaccines & beyond: a decade in mRNA delivery

Russell Johnson
30 January 2023
Read
Next steps for MSC innovation

Next steps for MSC innovation

Jacques Galipeau
18 January 2023
Read

FastFacts

Technology innovation to address challenges in gene therapy manufacture

Technology innovation to address challenges in gene therapy manufacture

Tania D Pereira Chilima
10 March 2023
Read

Viewpoint

Current trends in advanced therapy development & commercialization for rare diseases

Current trends in advanced therapy development & commercialization for rare diseases

Alan Boyd
28 February 2023
Read

Infographic

Eureca-V™ Nuclease: the wild-type MAD7® CRISPR Type-V nuclease licensed from Inscripta®

Eureca-V™ Nuclease: the wild-type MAD7® CRISPR Type-V nuclease licensed from Inscripta®

17 January 2023
Read

Poster

Optimizing vector production & purification to enhance scalable AAV manufacturing

Optimizing vector production & purification to enhance scalable AAV manufacturing

James Molinari, Jenny England
24 January 2023
Read

Corrigendum

Corrigendum to: thinking ahead: developing biosynthetic blood to anticipate donor drought

Corrigendum to: thinking ahead: developing biosynthetic blood to anticipate donor drought

24 January 2023
Read

Webinars